false
0001831868
0001831868
2026-11-11
2026-11-11
0001831868
icu:CommonStockParValue00001PerShareCustomMember
2026-11-11
2026-11-11
0001831868
icu:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockFor1150PerShareCustomMember
2026-11-11
2026-11-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): November 11, 2026
|
SeaStar Medical Holding Corporation
(Exact name of Registrant as Specified in Its Charter)
|
Delaware
|
001-39927
|
85-3681132
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
| |
|
|
|
3513 Brighton Blvd,
Suite 410
|
|
|
Denver, Colorado
|
|
80216
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
Registrant’s Telephone Number, Including Area Code: 844 427-8100
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock par value $0.0001 per share
|
|
ICU
|
|
The Nasdaq Stock Market LLC
|
|
Warrants, 250 whole warrants exercisable for one share of Common Stock for $2,875 per share
|
|
ICUCW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 11, 2026, SeaStar Medical Holding Corp. (the "Company") issued a press release announcing its financial condition and results of operations for the three and nine months ended September 30, 2026 (the "Press Release"). A copy of the Press Release is furnished as Exhibit 99.1.
On November 11, 2026, the Company hosted a webcast to discuss its financial and operating results for the quarter ended September 30, 2026. A transcript of the conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K. An archived webcast of the call will be available for three months after the event, at the web address provided in the Call Notice Press Release.
The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1 and Exhibit 99.2 is deemed to be “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is not otherwise subject to the liabilities of that Section, and shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
This Current Report on Form 8-K, including the exhibits hereto, contains statements that are forward-looking and as such are not historical facts. These statements are based on the beliefs and assumptions of management. Although we believe that our plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions, or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Generally, statements that are not historical facts, including statements concerning the possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. In some instances, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates” or “intends” or the negatives of these terms or variations of them or similar terminology. The forward-looking statements contained in this release are based on current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements are subject to a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results of performance to be materially different from those expressed or implied by these forward-looking statements, including those set forth under the caption “Risk Factors” section therein and in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
SeaStar Medical Holding Corporation
|
| |
|
By:
|
/s/ Eric Schlorff
|
|
Date:
|
November 12, 2026
|
Name:
|
Eric Schlorff
|
| |
|
Title:
|
Chief Executive Officer
|